Novo Nordisk A/S

Semaglutide Demonstrated Significant Reductions in Blood Sugar and Weight Compared with Dulaglutide; Results Published in The Lancet Diabetes & Endocrinology

Results from the SUSTAIN 7 trial, which investigated the efficacy and safety of 0.5 mg semaglutide compared with 0.75 mg dulaglutide and 1.0 mg semaglutide compared with 1.5 mg dulaglutide, when added to …

OTE0001
01.02.2018 09:32
 

Xultophy® Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy® (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six …

OTE0001
11.12.2017 09:03
 

Ryzodeg® Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg® (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe episodes by 62% and the rate …

OTE0003
07.12.2017 09:48
 

Tresiba® Reduces Hypoglycaemia Regardless of Blood Sugar Level

People with either type 1 or type 2 diabetes treated with Tresiba® had fewer episodes of low blood sugar (hypoglycaemia) compared with people on insulin glargine U100 regardless of whether they had …

OTE0002
07.12.2017 09:47
 

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, …

OTE0004
06.12.2017 09:03
 

Switching to Tresiba® Benefits People with Diabetes Irrespective of Blood Sugar Levels in a Real-world Setting

Switching to Tresiba® from another basal insulin benefits people with diabetes regardless of whether or not their blood sugar levels are controlled.[1] This is the conclusion of a post-hoc analysis of data …

OTE0003
05.12.2017 10:03
 

Xultophy® Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen).

OTE0001
05.12.2017 07:03
 

Xultophy® Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi

New findings from an indirect comparison between Xultophy® and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy® (insulin degludec/liraglutide) provides …

OTE0001
04.12.2017 07:57
 

New US Study Reveals Key Reasons why Millions of People with Obesity are not Receiving Adequate Care

Despite increasing recognition of obesity as a disease, many barriers to effective care remain

OTE0006
31.10.2017 13:03
 

IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

To mark World Heart Day today, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and …

OTE0002
29.09.2017 08:03
 
OTE0002
13.09.2017 16:33